Associations between the gut microbiome and fatigue in cancer patients.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 03 2021
Historique:
received: 15 11 2020
accepted: 18 02 2021
entrez: 13 3 2021
pubmed: 14 3 2021
medline: 15 12 2021
Statut: epublish

Résumé

Fatigue is the most prevalent symptom of cancer and its treatments. Changes in the intestinal microbiome have been identified in chronic fatigue syndrome and other neuropsychiatric disorders, and cancer patients. However, the association between intestinal microbiome and fatigue in patients with advanced cancers has not been evaluated. Understanding the connection between intestinal microbiome and fatigue will provide interventional and therapeutic opportunities to manipulate the microbiome to improve fatigue and other patients' reported outcomes. In this project, we aimed to identify associations between microbiome composition and fatigue in advanced cancer patients. In this cross-sectional observational study at a tertiary cancer care center, we included 88 patients with advanced, metastatic, unresectable cancers who were in a washout period from chemotherapy. We measured fatigue using the MD Anderson Symptom Inventory-Immunotherapy fatigue score, and used 16srRNA to analyze intestinal microbiome. Using correlation analysis we found that Eubacterium hallii was negatively associated with fatigue severity scores (r = - 0.30, p = 0.005), whereas Cosenzaea was positively associated with fatigue scores (r = 0.33, p = 0.0002). We identified microbial species that exhibit distinct composition between high-fatigued and low-fatigued cancer patients. Further studies are warranted to investigate whether modulating the microbiome reduces cancer patients' fatigue severity and improves their quality of life.

Identifiants

pubmed: 33712647
doi: 10.1038/s41598-021-84783-9
pii: 10.1038/s41598-021-84783-9
pmc: PMC7954807
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5847

Subventions

Organisme : NCI NIH HHS
ID : R01 CA242565
Pays : United States

Références

Front Microbiol. 2016 May 19;7:713
pubmed: 27242734
PLoS Comput Biol. 2015 May 07;11(5):e1004226
pubmed: 25950956
Br J Cancer. 1999 Mar;79(9-10):1479-86
pubmed: 10188894
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Brain Behav Immun. 2013 Mar;30 Suppl:S48-57
pubmed: 22776268
Leukemia. 2013 Jul;27(7):1511-9
pubmed: 23417029
J Clin Epidemiol. 1990;43(2):201-9
pubmed: 2303850
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33097611
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Support Care Cancer. 2011 Sep;19(9):1441-50
pubmed: 20706850
Int J Syst Evol Microbiol. 2011 Jul;61(Pt 7):1638-1644
pubmed: 20709916
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
Adv Med. 2020 Feb 7;2020:6375876
pubmed: 32090133
Endocrinol Nutr. 2016 Nov;63(9):482-494
pubmed: 27633133
Cancer. 2000 Oct 1;89(7):1634-46
pubmed: 11013380
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Mucosal Immunol. 2016 Nov;9(6):1455-1465
pubmed: 26982597
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Ann Gastroenterol. 2015 Apr-Jun;28(2):203-209
pubmed: 25830558
ISME J. 2012 Aug;6(8):1621-4
pubmed: 22402401
Nat Methods. 2013 Oct;10(10):996-8
pubmed: 23955772
J Clin Epidemiol. 2014 Jun;67(6):622-8
pubmed: 24508144
Cell. 2016 Nov 3;167(4):915-932
pubmed: 27814521
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
J Clin Oncol. 2007 Aug 1;25(22):3313-20
pubmed: 17664480
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Oncologist. 2000;5(5):353-60
pubmed: 11040270
Brain Behav Immun. 2016 Feb;52:145-152
pubmed: 26515035
Appl Environ Microbiol. 2005 Dec;71(12):8228-35
pubmed: 16332807
Cancer. 2003 Nov 1;98(9):1786-801
pubmed: 14584059
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Oncologist. 2003;8 Suppl 1:5-9
pubmed: 12626781
PLoS One. 2015 May 08;10(5):e0126312
pubmed: 25955845

Auteurs

Joud Hajjar (J)

Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
The William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, TX, USA.

Tito Mendoza (T)

Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Liangliang Zhang (L)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Siqing Fu (S)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Sarina A Piha-Paul (SA)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

David S Hong (DS)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Filip Janku (F)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Daniel D Karp (DD)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Alexej Ballhausen (A)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Jing Gong (J)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Abdulrazzak Zarifa (A)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Christine B Peterson (CB)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funda Meric-Bernstam (F)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Robert Jenq (R)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Aung Naing (A)

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. anaing@mdanderson.org.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH